Lopressor® (metoprolol tartrate) – New formulation approval

- On April 10, 2025, the FDA approved Validus Pharmaceuticals' **Lopressor (metoprolol tartrate) oral solution** in adult patients:
    - For the treatment of hypertension, to lower blood pressure
    - In the long-term treatment of angina pectoris in adult patients, to reduce angina attacks and to improve exercise tolerance
    - In the treatment of hemodynamically stable patients with definite or suspected myocardial infarction, to reduce the risk of cardiovascular mortality when used alone or in conjunction with intravenous metoprolol therapy.
- Metoprolol tartrate is a beta-adrenergic blocker that is available generically as an oral tablet.
- Lopressor is contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure < 100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.
- Warnings and precautions for Lopressor include abrupt cessation of therapy, heart failure, bronchospastic disease, pheochromocytoma, major surgery, hypoglycemia, thyrotoxicosis, risk of anaphylactic reaction, and peripheral vascular disease.
- The most common adverse reactions with Lopressor use are tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, and rash.
- Refer to the Lopressor drug label for complete dosing and administration recommendations.
- Validus Pharmaceuticals' launch plans for Lopressor are pending. Lopressor will be available as a 10 mg/mL oral solution.